You are now leaving the pages of www.gilead.com intended for U.S. audiences. The information in this section is intended for visitors outside the United States.
Gilead Sciences and Triangle Pharmaceuticals Announce Expiration of Hart-Scott-Rodino Waiting Period
Gilead to Receive $300 Million from Offering of Convertible Notes
Gilead to Raise $300 Million From Offering of Convertible Notes
Gilead Sciences to Acquire Triangle Pharmaceuticals for $464 Million
European CPMP Gives Positive Opinion On Hepsera, Gilead's Treatment for Chronic Hepatitis B; Recommendation Granted Eight Months After Filing
New Data Demonstrate Antiviral Activity of Gilead's Hepsera in Patients with Lamivudine-Resistant Chronic Hepatitis B
Gilead Sciences Announces Third Quarter 2002 Financial Results
Gilead Sciences to Release Third Quarter 2002 Financial Results On Thursday, October 31, 2002; Conference Call and Webcast to Follow
Phase III Study of Viread Shows Favorable Lipid and Mitochondrial DNA Profile in Treatment-naive HIV Patients; Data Presented in Late-Breaker Session at 42nd ICAAC
FDA Approves Gilead's Hepsera(TM) for the Treatment of Chronic Hepatitis B
Hepsera Selected as U.S. Trade Name for Adefovir Dipivoxil
FDA Advisory Committee Unanimously Supports Approval of Gilead's Adefovir Dipivoxil to Treat Chronic Hepatitis B
Gilead Announces Posting of FDA Briefing Documents for August 6 Advisory Committee Review of Adefovir Dipivoxil for Chronic Hepatitis B
Gilead Sciences Announces Second Quarter 2002 Financial Results; Strong Viread Sales Push Total Revenues Past $100 Million, Lead to Profitability
Gilead Sciences to Release Second Quarter 2002 Financial Results On Wednesday, July 24, 2002; Conference Call and Webcast to Follow
48-Week Data Demonstrate Ability of Viread to Suppress Viral Load in Patients With Multiple Treatment-Resistant HIV Mutations
48-Week Data Compare Viread to Stavudine When Used as Part of Patients' First Anti-HIV Regimen; Data Presented at XIV International AIDS Conference in Barcelona
Roche Receives Approval in Europe for Tamiflu(R)
Gilead Sciences Announces Acceptance of Viread Late Breaker Abstracts At Upcoming 14th International AIDS Conference
Anadys Forms Collaboration With Gilead to Discover Novel Antiviral Compounds; Anadys' uHTS-ATLAS to be Used to Screen Important and Challenging Viral Target
Webcast Alert: Gilead Sciences, Inc. Announces Its Annual Meeting of Stockholders Conference Call on the Web
Gilead Announces Initiation of NIH-sponsored Phase I Trial to Evaluate Tenofovir Topical Gel as Preventive for Vaginal Transmission of HIV
Gilead Announces Preliminary 48-Week Study Results Showing Viread Comparable to Stavudine in Treatment-Naive HIV Patients
Gilead Sciences Announces First Quarter 2002 Financial Results; Product Revenues Include $27.2 Million in Viread Sales
Gilead and GlaxoSmithKline Announce International Licensing Agreement for Investigational Chronic Hepatitis B Drug Adefovir Dipivoxil
Data From Study of Gilead's Adefovir Dipivoxil in Hepatitis B Patients With Lamivudine-Resistant Virus Presented At International Medical Meeting
92-Week Data From Clinical Study of Gilead's Adefovir Dipivoxil in Patients Co-Infected With HIV and Lamivudine-Resistant HBV Presented At International Medical Meeting
Gilead Announces Presentation of Data From Phase III Study of Adefovir Dipivoxil in Patients With Precore Mutant Chronic Hepatitis B
Gilead Sciences to Release First Quarter 2002 Financial Results On Tuesday, April 30, 2002; Conference Call and Webcast to Follow
Gilead Announces Changes to Senior Management Team; Organization Positioned for Continued Growth
Gilead Submits Marketing Authorisation Application for Adefovir Dipivoxil 10 mg for Treatment of Chronic Hepatitis B; EU Application Follows Submission to FDA
Gilead Submits New Drug Application to U.S. FDA for Adefovir Dipivoxil 10 mg for the Treatment of Chronic Hepatitis B
Roche Receives Positive Recommendation in Europe for Tamiflu(R)
Gilead Initiates Early Access Program for Adefovir Dipivoxil, Investigational Treatment for Chronic Hepatitis B Infection
Gilead Announces Data From Study of Viread in Patients Co-infected With HIV and HBV; Data Presented at 9th Conference on Retroviruses and Opportunistic Infections
Viread Demonstrates Anti-HIV Potency Similar to the Protease Inhibitor Ritonavir in Short-Term Study of Treatment-Naive Patients
Gilead Sciences' Viread Suppresses HIV Viral Load Through 48 Weeks in Phase III Clinical Trial
Gilead Launches Web Site for New Anti-HIV Drug Viread
Gilead Sciences' New HIV Drug Viread Approved for Marketing in European Union
Gilead Sciences Announces Fourth Quarter and Year End 2001 Financial Results; Product Revenues Increased 57 Percent Over Fourth Quarter 2000
Gilead Board of Directors Approves Two-for-One Stock Split
Gilead Sciences to Release Fourth Quarter and Year-End 2001 Financial Results On Thursday, January 31, 2002; Conference Call and Webcast to Follow
2012 Interactive Annual Report